We only have this paper's title and publication details.
Read it at the sourceClinical review details immune toxicities in cancer patients receiving CAR-T and bispecific T-cell engagers, highlighting essential diagnostic and management strategies.
No takes yet. Share an insight, caveat, or question.
Carter et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: